undamentalytics Newsletter
Sign in

Bausch Health Companies Inc. revenue

Bausch Health Companies Inc.'s revenue was $10.27bn in fiscal 2025, up 6.7% on the year before. Since fiscal 2009 ($820m) it has grown at a compound 17.1% a year. Over the last twelve months it was $11.11bn.

Revenue history

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue0.81.22.43.55.88.210.49.78.78.48.68.08.48.18.89.610.311.1
Growth on the year before—+44.0%+105.5%+43.4%+65.8%+42.2%+27.3%−7.4%−9.8%−3.9%+2.6%−6.7%+5.1%−3.7%+7.8%+9.9%+6.7%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Bausch Lomb $5.1B 49.7% ▲ 6.5%
Salix $2.6B 25.1% ▲ 10.5%
International Rx $1.1B 11.0% ▲ 1.9%
Diversified $937M 9.1% ▼ 1.4%
Solta Medical $518M 5.0% ▲ 17.7%
Products and services
Line of business Revenue Share YoY
Products $10.2B 97.9% ▲ 6.7%
Pharmaceutical Products $4.7B 46.7% ▲ 8.0%
Device Products $2.4B 24.0% ▲ 8.9%
Overthe Counter Products $2B 19.8% ▲ 5.5%
Branded and Other Generic Products $962M 9.5% ▼ 1.7%
Other $110M 1.1% ▲ 2.8%
Other Revenues $110M 1.1% ▲ 2.8%
Geography
Region Revenue Share YoY
United States and Puerto Rico $6.1B 59.8% ▲ 6.4%
Other Countries $1.2B 11.2% ▲ 6.5%
China $493M 4.8% ▼ 0.6%
Canada $417M 4.1% ▲ 3.7%
PL $382M 3.7% ▲ 9.1%
Mexico $278M 2.7% ▼ 11.7%
France $249M 2.4% ▲ 8.3%
South Korea $234M 2.3% ▲ 60.3%
RU $198M 1.9% ▲ 23.0%
Japan $192M 1.9% ▲ 2.1%
Germany $176M 1.7% ▲ 10.7%
United Kingdom $141M 1.4% ▲ 4.4%
ES $109M 1.1% ▲ 10.1%
IT $106M 1.0% ▲ 12.8%

From Bausch Health Companies Inc.'s 10-K filed February 19, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Bausch Health Companies Inc. $11.11bn 10.8% 9.2%
Zoetis $9.52bn 1.5% 5.0%
Haleon plc $14.55bn 1.3% —
Viatris $14.74bn 4.4% -1.9%
Universe Pharmaceuticals Inc $17.86bn -22.4% —
Organon & Co. $6.10bn -3.2% -0.3%

Compare with peers

Head to head: BHC vs ZTSBHC vs HLNBHC vs VTRSBHC vs UPC

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Bausch Health Companies Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bausch Health Companies Inc.